Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The ... - Yahoo Finance
| 095700 Stock | KRW 5,880 230.00 4.07% |
About 56% of Genexine's investor base is looking to short. The analysis of current outlook of investing in Genexine suggests that many traders are alarmed regarding Genexine's prospects. The current market sentiment, together with Genexine's historical and current headlines, can help investors time the market. In addition, many technical investors use Genexine stock news signals to limit their universe of possible portfolio assets.
Genexine |
Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The ... Yahoo Finance
Read at news.google.com
 |
Genexine Fundamental Analysis
We analyze Genexine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genexine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genexine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Genexine is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Genexine Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Genexine stock to make a market-neutral strategy. Peer analysis of Genexine could also be used in its relative valuation, which is a method of valuing Genexine by comparing valuation metrics with similar companies.
Complementary Tools for Genexine Stock analysis
When running Genexine's price analysis, check to measure Genexine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genexine is operating at the current time. Most of Genexine's value examination focuses on studying past and present price action to predict the probability of Genexine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genexine's price. Additionally, you may evaluate how the addition of Genexine to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |